Paper Details

  1. Home
  2. Paper Details

The promises and pitfalls of reboxetine.

Author: PageMichelle E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Reboxetine, a selective noradrenergic reuptake inhibitor, is a promising antidepressant with fewer side effects than older antidepressants like tricyclic antidepressants (TCAs). While reboxetine has been approved in Europe, further development in the US has been halted despite its positive pharmacological profile. Nevertheless, reboxetine serves as a valuable tool for preclinical research on the role of the noradrenergic system in depression.
Paper Details　
Original Abstract of the Article :
The antidepressant compound, morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-,methanesulfonate, or reboxetine, is a selective noradrenergic reuptake inhibitor that acts by binding to the norepinephrine (NE) transporter and blocking reuptake of extracellular NE back into terminals. This compound has lo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1527-3458.2003.tb00258.x

データ提供：米国国立医学図書館（NLM）

Reboxetine: Promises and Pitfalls of a Selective Noradrenergic Reuptake Inhibitor

The journey to develop effective treatments for depression is often riddled with complexities and challenges. This research, a trailblazer in the desert of antidepressant research, explores the potential of reboxetine, a selective noradrenergic reuptake inhibitor, as a novel treatment for depression.

A Selective Approach: Targeting the Noradrenergic System

Reboxetine, like a meticulous desert explorer, specifically targets the norepinephrine (NE) transporter, effectively blocking the reuptake of NE back into nerve terminals. This selective action sets it apart from older antidepressants, which often interact with other neurotransmitter systems, leading to a wider range of side effects.

The Promise and the Pause: A Journey with Reboxetine

Despite its promising pharmacological profile, reboxetine's journey as an antidepressant has been marked by both progress and setbacks. While it gained approval in several European countries, its path in the United States has been more challenging. The reasons for this pause in its development remain unclear, leaving researchers and patients alike pondering the future of this potentially valuable antidepressant.

Health Implications and Everyday Life: Navigating the Desert of Depression

This research, a glimpse into the complex world of antidepressants, highlights the importance of understanding the nuances of neurotransmitter systems in mental health. While reboxetine's future remains uncertain, it serves as a reminder of the ongoing quest for effective and well-tolerated treatments for depression. For individuals seeking relief from depression, navigating the desert of mental health requires careful consideration of available treatment options and open communication with healthcare professionals.

Dr. Camel's Conclusion

This research, a testament to the ever-evolving landscape of antidepressant therapy, underscores the importance of both selectivity and specificity in targeting neurotransmitter systems. While reboxetine's journey as an antidepressant has been marked by twists and turns, it serves as a valuable reminder that the search for effective treatments for depression is a continuous and evolving process.

Date :
  1. Date Completed 2004-01-20
  2. Date Revised 2020-02-25
Further Info :

Pubmed ID

14647527

DOI: Digital Object Identifier

10.1111/j.1527-3458.2003.tb00258.x

Related Literature

Article Analysis
・Side Effects of maprotiline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.